Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Operating Expenses came in at $75.2 million in Q1 2026, up 18.99% YoY from $63.2 million in Q1 2025, and up 8.95% on a QoQ basis from $69.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Operating Expenses (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Operating Expenses data on file, last reported at $75.2 million in Q1 2026.
- Quarterly Operating Expenses rose 18.99% year-over-year to $75.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $279.0 million (up 13.84% YoY) and the FY2025 annual result came in at $266.9 million, up 12.77% from the prior year.
- Operating Expenses advanced to $75.2 million in Q1 2026, from $69.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $75.2 million in Q1 2026 to a low of $44.2 million in Q2 2022.
- A 5-year average of $57.6 million and a median of $54.9 million in 2024 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 105.12% in 2022, down 30.68% in 2022.
- Tracing XERS's Operating Expenses over 5 years: stood at $48.3 million in 2022, then gained by 12.25% to $54.2 million in 2023, then increased by 7.72% to $58.4 million in 2024, then gained by 18.17% to $69.0 million in 2025, then rose by 8.95% to $75.2 million in 2026.
- The last three Operating Expenses figures came in at $75.2 million (Q1 2026), $69.0 million (Q4 2025), and $67.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.50 Bn | 1.38 Bn | 79.59 Mn | 86.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.93 Mn |
| Mar 31, 2026 | 75.21 Mn |
| Dec 31, 2025 | 69.03 Mn |
| Sep 30, 2025 | 67.65 Mn |
| Jun 30, 2025 | 67.06 Mn |
| Mar 31, 2025 | 63.21 Mn |
| Dec 31, 2024 | 58.42 Mn |
| Sep 30, 2024 | 67.16 Mn |
| Jun 30, 2024 | 56.25 Mn |
| Mar 31, 2024 | 54.88 Mn |
| Dec 31, 2023 | 54.23 Mn |
| Sep 30, 2023 | 53.23 Mn |
| Jun 30, 2023 | 53.99 Mn |
| Mar 31, 2023 | 46.47 Mn |
| Dec 31, 2022 | 48.31 Mn |
| Sep 30, 2022 | 48.51 Mn |
| Jun 30, 2022 | 44.22 Mn |
| Mar 31, 2022 | 51.15 Mn |
| Dec 31, 2021 | 69.70 Mn |
| Sep 30, 2021 | 35.42 Mn |